Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Lavinia Arseni(German Cancer Research Center), Martina Seiffert(German Cancer Research Center), Mikhail M. Savitski(European Molecular Biology Laboratory), Yashna Paul(German Cancer Research Center), Stephan Stilgenbauer(Universität Ulm), Eugen Tausch(Universität Ulm), S. Öhl(German Cancer Research Center), Haniyeh Yazdanparast(German Cancer Research Center), Eric Eldering(Amsterdam University Medical Centers), Mathias Kalxdorf(German Cancer Research Center), Verena Kalter(German Cancer Research Center), Marc Zapatka(German Cancer Research Center), Sascha Dietrich(European Molecular Biology Organization), Peter Lichter(German Cancer Research Center), Gianluca Sigismondo(Heidelberg University), Arnon P. Kater(Amsterdam University Medical Centers), Ingo Ringshausen(University of Cambridge), Sigrid S. Skånland(Oslo University Hospital), Johanne U. Hermansen(Oslo University Hospital), Dennis Friedel(German Cancer Research Center), Mandy Rettel(European Molecular Biology Organization), Murat Iskar(German Cancer Research Center), Norman Mack(German Cancer Research Center), Philipp M. Roessner(German Cancer Research Center), Jeroen Krijgsveld(German Cancer Research Center), Julie Dubois(University of Fribourg)
Cited by 5
Related Papers
Mass-spectrometry-based draft of the human proteome
|Nature|2014|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k